Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Theo, DougS and I are the moderators for this board! John has stepped down to concentrate on the other boards that he moderates for here at Ihub. If you have any concerns about posts on "THIS BOARD," please private message one of us! Have a good day and happy trading to you!
IVRT
I am finally glad to see you folks posting here. It has been lonely over here, but the lack of BS from RB has made the months refreshing here. I want to welcome you to the DNAP board. We can delete many messages such as spam and abusive language and etc.
If you have issues with fellow posters here, please use the private reply button amongst yourselves or email sysop for help. Over the last year or two we have had minimal problems with spam and wholesale idiotic posters.
Glad to see some of the old DNAP posters here as well as new ones too!
IVRT
Looks great John :)! eom
Jmhollen is the new DNAP board assistant! Not a big thing, but I wanted to let everyone know. I have not heard from cerealman in along time, and removed him accordingly!
Have a good day all!
IVRT
The Revolution in Forensic Genomic Starts Now
DETERMINE RACE PROPORTIONS FROM CRIME SCENE DNA
- The Revolution in Forensic Genomic Starts Now -
DNAPrint genomics, Inc. has applied the most recent advancements in human genomic technology for the deciphering of an individual's race. We are proud to introduce to the forensic community DNA WITNESS 2.0, a genetic test for the deduction of the heritable component of race, called Biogeographical Ancestry (BGA). This test is the first of its kind, resulting from three (3) years of genomic research, and is the beginning of a revolution in criminal investigations. This test provides not only the majority population affiliation (i.e. Indo European, Sub-Saharan African, East Asian or Native American), but the admixture, as well (i.e. 82% East Asian and 18% Indo-European mix).
This new test provides important Forensic Anthropological information relevant for a wide variety of investigative situations. When biological evidence is gathered, an investigative team can use DNA WITNESS 2.0 to construct a partial physical profile from the DNA and in many cases learn details about the donor's appearance, essentially permitting a partial reconstruction of their driver's license photo. How many times have you wished an unknown suspect left his driver's license at the scene - even if the unique identifiers were smudged?
Recognizing the need for genomics-based physical profiling tools, DNAPrint genomics is the first company to apply human genome power for the precise estimation of Biogeographical percentages from DNA.
Because physical profiling from DNA will effectively offer an objective "eyewitness" for each crime, where biological evidence has been left, the implications for saving investigative dollars and maximizing the efficiency of our criminal justice system are profound. STR identity tests form the cornerstone of forensic DNA analysis, but they are not useful for the assumption of race or any other physical traits, because the STR markers were not selected for the ability to do so. Other non-DNA based investigative work tends to rely on less scientifically robust methodology. For example, "eyewitnesses":
" Are not always reliable, are subjective and sometimes misleading. Most of the felons released from death row, based on DNA testing, were convicted based on faulty eyewitness testimony.
" Are not available for each crime.
Until now, no scientific method has been available to help investigators learn what a DNA donor looks like. DNAPrint's DNA WITNESS 2.0 product represents the first wave of a genomics revolution that is afoot in forensics science. We are applying the test to actual casework and we've performed testing for a number of high profile murder/rape cases, where DNA was left at the crime scene.
DNA WITNESS 2.0 could provide additional detail to current cases or cold cases could be re-visited. The results indicating to detectives what population groups to include or exclude in their investigation. The goal of the product is simple, help you focus your investigation and identify from whom a forensic sample was derived. Effectively, what we have done is harness our increasing knowledge of human genomics to help you get the job done. Wouldn't you like to have a DNA eyewitness for your most important cases?
We would be pleased to provide you a CD-ROM of the validation experiments, which was performed for this test on over 2,000 DNA samples.
Please contact us to discuss the possibility of using DNA WITNESS 2.0 on your cold, current, or next case.
Zach Gaskin
Technical Director, Forensic Genomics
941-366-3400
zgaskin@dnaprint.com
Copyright DNAPrint genomics © 2000
900 Cocoanut Ave.
Sarasota, FL 34236
(941) 366-3400
Fax # (941) 952-9770
GPXME moving, up 0.08 on news! http://finance.lycos.com/home/news/story.asp?story=34280683
DNAPrint Launches Ancestry 2.0 Forensic Profiling Service and Immediately Impacts Several Criminal Investigations
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cpr%5C2003%5C05%5C02...
DNAPrint genomics Appoints Richard Gabriel as President and CEO
http://finance.lycos.com/home/news/story.asp?story=33782252
Happy New Year 2003!!!!!!!!!!
DNAPRINT GENOMICS INC 0001127354 10QSB
http://www.pinksheets.com/quote/print_filings.jsp?url=%2Fredirect.asp%3Ffilename%3D0001070876%252D02...
Phil Brooks as the Company's first marketing director.
DNAPrint Enters Into Development Site Agreement With Nanogen to Develop DNA Chip Based Tests
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cbw%5C2002%5C10%5C29...
DNAPrint Launches ANCESTRYbyDNA 2.0 - World's First Recreational Genomics Testing Service
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cbw%5C2002%5C09%5C19...
The new DNAP newsletter:
Dear Shareholders,
I am happy to send you our second company newsletter. First, let me say that I consider DNAPrint’s scientific achievements thus far to be a great success. Rest assured, however, that our efforts are just beginning. We have written, applied and patented some of the most algorithmically complex and advanced genomics data analysis programs on the planet. In one year, these algorithms have helped us solve genetic problems (such as variable human iris color) that had perplexed geneticists for decades. I believe that your investment has helped create a formidable player in the genomics based testing market.
The Company has seen many developments since our last newsletter. We have changed the composition of our Board, announced several new scientific partners, and announced the discovery of three new forensics classifiers and their imminent product launches. We have also achieved a significant equipment upgrade that reduced our overhead and accelerated our throughput - at no cost to us. Further, we announced our foray into commercial genotyping, which we expect will help establish a revenue base upon which to grow. I will discuss some of these items one by one:
RETINOME - We have announced our intention to have either a beta trial or a partnership with a large company in place by the end of the year. This is an important part of our business strategy you should understand. We would prefer to partner our products with capable partners so we can devote ourselves to discovery and grow our revenue base more rapidly. However, if we cannot obtain satisfactory terms from a prospective partner, we will market a given test ourselves. This would provide us more profit from each test, but would increase product development costs and reduce the number of tests we could develop. We are currently in discussions with four large corporations to help us commercialize this test.
On a different note, my recent Washington D.C. presentation for RETINOME was very well received. In fact, I sensed that people are shocked that such a small company could do what we have done. Realize that RETINOME is the first complex genetics classifier to be presented in the post human genome age. Larger companies with more resources have yet to announce such a development - some have announced SNPs or haplotype associations, but we are the first to present a complex genetics classifier that performs well upon blind challenge. This bodes very well for our ability to make drug classifiers since most of these will also be complex! As we have always maintained, the key is our math.
OVANOME - Earlier this year, our University of Miami collaborators and I presented the results of our Ovarian Cancer pharmacogenomics study at the Society of Gynecological Oncology Miami and at BIOIT Boston. Our study is unique because we are focused on the variable response to firstline treatment (a pharmacokinetic problem, not a tumor genetics problem). To my knowledge, we are the only company with successful results there. We have applied for an NIH grant to fund a prospective trial at Miami, the data from which will go into an FDA application so that we could be approved to sell the kits. Until this process is complete, we will offer Taxol genotyping services (preferably through a licensee), which are not subject to FDA regulation. This brings up a second point that you should understand about our drug classifier strategy (as opposed to our forensics test strategy). For each kit we produce, there will be a service phase and a supply phase. Making an FDA approved kit (i.e., the supply phase) is more profitable, but it takes time to get kits approved by the FDA. So, until we receive FDA approval for our drug classification kits, we will perform services using our kits ourselves (i.e., the service phase). Companies like Myriad Genetics have had great success performing genetics testing services. In the case of the Taxol classifier, our licensees and affiliates will begin performing classifications for prospective Taxol patients at the University of Miami while we compile the FDA application. We will add future customer sites based on customer satisfaction at the primary sites, and we hope that word of mouth will travel fast since peoples’ lives are at stake. We believe that this service/supply commercialization model will help us maximize return on investment.
OTHER TESTS - We have finished both the genotyping and the computational screening for Lipitor and Zocor, and we have finished the genotyping but not the computational screening for about 15 other drugs we have good sample sizes for. As we complete these projects, we will disclose the results within a formal, peer-reviewed setting such as a professional meeting or in the scientific literature.
SNPs - From a screen of thousands of SNPs, we have settled on a panel of 346 SNPs in about 50 xenobiotic metabolism genes for our pharmacogenomics screening. These SNPs have good characteristics (minor allele frequencies) for the sample sizes we employ - which mean they are of potentially good statistical use. Validated SNP panels like this one, of potential statistical value, are not easy to find and impossible to purchase - the chip-based sets available commercially typically apply onlyto a few cytochrome P450s, but our set covers 50 genes. We are quite proud of this panel.
ACADEMIC DEALS - We have inked new deals with the New York University and Penn State University, and added a world-renowned geneticist to our Scientific Advisory Board. These agreements supplement our existing agreement with the University of Miami. The fact that some of the nation’s leading medical universities want to work with DNAPrint speaks highly of our science.
CORPORATE - Earlier in the year, we changed the composition of our board of directors. Our new board members are providing top-notch advice and are prospecting for new deals and corporate investors. To help with this, we have consulted with professionals to greatly simplify and update our business/marketing plan. Our existing $2M funding source for the next year or so has so far been quite reliable (about $650,000 of it has so far been funded). I think it reflects favorably on our company that friends, officers and directors prefer to fund it rather than offer the opportunity to an outside venture group. We are currently evaluating and planning for our research needs after the existing funding term, and we will continue discussing this topic in the upcoming months.
OTHER ITEMS - So far, we have filed for a total of 8 patents - 5 mathematical methods/software patents and 3 classifier patents. Four of these have been converted to date to regular utility patent applications, the other four are to be converted within the year. We add data to each provisional over the course of time to make it as strong as possible before converting it. The patent process is an ongoing process, of course, as they naturally flow from our work here. The patents filed here at DNAPrint are my life's greatest scientific achievements, by far. Mostly because of the challenging level on which the work has been performed, I find them more rewarding than others I have been involved with in the past. We have written 2 scientific manuscripts and are writing a third. For products that may be partnered, the publication dates are set through the process of negotiation (i.e. we are not a University and we do not rush to publish everything we have as soon as we have it.). We have 4 grant applications pending at present and 2 more in preparation.
While we cannot control the financial markets or the financial performance of our partners, we can control the quality of work we do. We believe our share price will ultimately reflect this quality, in addition to the quality of our business decisions. Keep in mind, however, that our aim is to build a company for the long term. I know most of you are long-term investors, and it is with your interests in mind that we shape every decision made here. I think we have performed well to date and I hope you agree.
Until the next newsletter then,
Respectfully,
Tony
Next DNAP conference: June 24-28, 2002 in Washington D.C., and at the National Managed Health Care Congress (NMHCC) "Disease Management Congress" to be held September 16-20 in Chicago, IL.
http://www.dnaprint.com/pr_retinome.html
You can access the ABC DNAP videos from DNAP's web page now. http://www.dnaprint.com./
Capitalizing on the next cholesterol blockbuster drugs
Interesting read...
http://www.siliconinvestor.com/insight/editorial.gsp?id=65203
Sarasota company buys DNA samples
http://www.heraldtribune.com/frontpage/story.cfm?ID=67969
DNAPRINT GENOMICS INC 10KSB
http://www.pinksheets.com/quote/filings.jsp?symbol=DNAP
Trading stocks is the game!!! DNAP is my favorite stock to trade!!!
Discovery may help to fight ovarian cancer
http://www.heraldtribune.com/business/d-index.cfm
Focused Plenary Session on Ovarian Cancer
http://www.sgo.org/meetings/33annual/abstracts/abstract.asp?abstractid=21
Determination of a Candidate Gene in Predicting In-Vivo Ovarian Cancer Response to Combination Therapy with Carboplatin and Paclitaxel
Ramin Mirhashemi*, J Fernando Arena, Tony Frudakis, Nicholas Lambrou, Jane Arboleda, Marsha Hunt, Hervy E Averette, Manuel A Penalver. Univ of Miami, Sch of Medicine, Miami, FL, DNAPrint Genomics, Sarrasota, FL.
Objectives: Patient response rates to primary treatment of ovarian cancer with combination of paclitaxel and the carboplatin agents is subject to a high degree of uncertainty and inter-individual variability. In an attempt to define the genetic determinants for this variability, we are conducting a pharmacogenomics study to predict response based on patient genomics.
Methods: Our approach is a systematic haplotype-based candidate gene approach, where we genotype each patient at each single nucleotide polymorphic (SNP) site for each gene known to be relevant for xenobiotic disposition, then computationally infer haplotypes, and geometrically model the data in order to identify associations between haplotypes and response. We have chosen this novel approach to objectively define an optimal pharmacogenomics solution.
Results: We have constructed SNP maps for 50 genes known to be involved in xenobiotic metabolism and/or the disposition of paclitaxel and carboplatin and have discovered an average of 30 candidate SNPs per gene, which, upon polymorphism screening, validated at a rate of about 18 SNPs per gene. Having obtained genotypes for 57 patients at each of the SNPs in several genes, preliminary results have revealed a statistically significant association (Fishers Exact p=0.00332 ± 0.00043) between haplotypes at the CYP3A4 gene and a lack of response to paclitaxel/carboplatin as measured by the CA-125 tumor marker. In particular, the GAC and GAT CYP3A4 haplotypes were only present in the non-responder group (n=22), when an absolute decrease in CA-125 was used to define responders (n=40). When a 20% decrease in CA-125 was used, a similar result was obtained (Fishers Exact p=0.016 ± 0.001); GAC was found in the non-responder group 71% of the time, and the GAT haplotype was found in the non-responder group 100% of the time.
Conclusions: SNPs in candidate genes being identified could potentially be used pre-treatment to individualize chemotherapy for patients with ovarian cancer. This in vivo assay could help classify ovarian cancer patients as potential responders or non-responders to our conventional chemotherapeutic agents.
Society of Gynecologic Oncologists
401 N. Michigan Avenue
Chicago, IL 60611
(312) 644-6610
E-mail: sgo@sba.com
( BW)(MA-DNAPRINT-GENOMICS)(DNAP) DNAPrint Presents Paclitaxel Response Study Results at BioITWorld Expo; Response to Common Ovarian CancBusiness Editors & Health/Medical Writers
BIOWIRE2K
BioITWorld 2002
BOSTON--(BW HealthWire)--March 14, 2002--DNAPrint genomics, Inc. (OTCBB:DNAP) announced today successful results from an ongoing collaboration with the University of Miami aimed at identifying the genetic basis for variable paclitaxel (Taxol) response in cancer patients. Dr. Tony Frudakis, Chief Executive Officer of DNAPrint genomics presented the results at the BioITWorld Expo in Boston, MA on March 14th.
"We've identified a set of variant human genes that we believe can be used to predict therapeutic outcomes for paclitaxel," said Dr. Tony Frudakis, CEO of DNAPrint genomics. "Given the consequences of inefficacy, it will be of great value to know when treatments based on population means should not be prescribed."
As currently administered, roughly 30% of ovarian cancer patients fail to respond to paclitaxel (Taxol)-based combination treatments during first line chemotherapy. Genetic tests, focused on the part of the genome known to be involved in drug metabolism, were performed on ovarian cancer patients that responded to the treatment and the results compared to those that did not. Haplotype sequences in two genes that are associated with non-response were identified.
Management believes that the results presented at the meeting constitute the core for developing a predictive genetic test called the OVANOME classifier, which could be used to economically evaluate the suitability of cancer patients for standard doses of paclitaxel chemotherapy during first line treatment for ovarian cancer. The test may have implications for enhancing first line chemotherapy success rates for patients with a variety of cancer types.
Doctors from the University of Miami will present the results on March 19th at the 33rd annual meeting of the Society of Gynecologic Oncologists in Miami, FL. For the past year, DNAPrint has been collaborating with the University of Miami Familial Ovarian and Breast Cancer Center in Miami, FL, to identify the complex genetic determinants for variable paclitaxel response in ovarian cancer patients. DNAPrint has already received a grant to extend these results in-vitro, using a model system for paclitaxel response, and is teaming with the University of Miami to fund additional work aimed at validating the value of the test for guiding patient treatment decisions.
About DNAPrint genomics, Inc.
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and statistical modeling, programming and molecular genetics. Our quest is to become the leader in the development of complex pharmacogenomics classifiers for a personalization of drug prescription. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
--30--pp/mi*
CONTACT: DNAPrint genomics, Inc., Sarasota
Investor Contact: Carrie Castillo, 941/366-3400
ccastillo@dnaprint.com
or
Media Contact: Russell LaMontagne, 212/219-0800
russell@corinthgroup.com
KEYWORD: FLORIDA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL EDUCATION
TRADESHOW
SOURCE: DNAPrint genomics, Inc.
er Treatment Shows Strong Genetic Basis
DNAPrint Files Patent for Complex Genomics Algorithm
http://www.investors.com/newswire/nwnp01.asp
GenoMed, Inc. Adds Tony Frudakis, Ph.D. to Scientific Advisory Board
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cbw%5C2001%5C12%5C07...
DNAPrint Collaborates with NYU School of Medicine
SARASOTA, Fla., Dec 3, 2001 /PRNewswire via COMTEX/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) announced today that it has entered into a collaboration with the New York University School of Medicine to develop pharmacogenomic classifiers for organ transplant patients.
NYU's Mary Lea Johnson Richards Organ Transplantation Center will provide DNAPrint with informed consent qualified patient specimens and matching clinical data. DNAPrint will genetically screen the specimens for markers and/or marker sets that can be used to distinguish between drug responders and non-responders. To do this, the company will employ proprietary genotyping protocols, data resources (the PHENOME SNP database) and its powerful informatics platform.
The goal of the project is to identify pharmacogenomic classifiers that could be used to match renal transplantation patients with the optimal immunosuppressant for their genetic architecture. The project is expected to take about one year to complete, and the results are expected to extend to patients for a wide range of transplantation procedures.
About NYU's Transplant Program:
The Mary Lea Johnson Richards Organ Transplantation Center is one of the busiest and most successful transplant programs in the United States. The program offers transplantation of the liver, kidney and pancreas and performs about 150 transplants annually. Over 500 liver and 200 kidney transplants have been done since program inception and the programs graft and patient survival rates are consistently among the best in the country.
About DNAPrint genomics, Inc.:
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and statistical modeling, programming and molecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.
Investor Relations Inquiries please contact:
Tim Wilkins
941/341-0136
twilkins@tbfcorp.net
Or
Carrie Castillo
ccastillo@dnaprint.com
941/366-3400
For Scientific Inquiries, please call:
Dr. Tony Frudakis
941/366-3400
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X19415882
SOURCE DNAPrint genomics, Inc.
CONTACT: Investor Relations: Tim Wilkins, +1-941-341-0136,
twilkins@tbfcorp.net, or Carrie Castillo, +1-941-366-3400,
ccastillo@dnaprint.com, or Scientific Inquiries: Dr. Tony Frudakis,
+1-941-366-3400, all for DNAPrint genomics Inc.
URL: http://www.dnaprint.com
http://www.prnewswire.com
Copyright (C) 2001 PR Newswire. All rights reserved.
Thank you sarals
DNA Print brings genetic eye test product to market
http://www.newscoast.com/2biz.cfm?ID=55108
DNAPrint Genomics 'Solves' Human Eye Color and Announces
http://quote.bloomberg.com/fgcgi.cgi?T=marketsquote99_news.ht&s=AO914ixO3RE5BUHJp
You guys should look at the prs released after the conference last October. DNAP will mostly like repeat this pattern again. What we will find out is that the platform is finish and one or two solutions are ready to market in the next year or one year and one-half. DNAP s/p will go up (permanently) when ORCH or others see real value in DNAP products. Question is: what value will be placed on the post conference information Dr. Tony gives this weekend?
Happy trading too!!!
DNAPrint (OTC Bulletin Board: DNAP) to Present at Upcoming Conferences
http://quote.bloomberg.com/fgcgi.cgi?T=marketsquote99_news.ht&s=AO8yMqwz5L0MgTyBS
Cariocca, you said it best. I am lucky to be living in a changing world. One that is full of surprises. I hope DNAP is full of wonderful surprises for us!
Selected papers for further reading about Phenomics:
Alizadeh et. al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 403: 503-511.
Schilling, C., Edwards, J., and B. Palsson. Toward metabolic phenomics: Analysis of genomic data using flux balances. Biotechnol. Prog. 1999, 15:288-295.
Strothman, R.C. The coming Kuhnian revolution in biology. Nat. Biotechnol. 1997, 15, 194-200.
Fields, S. The future is function. Nat. Genet. 1997, 15, 325-327.
Hieter, P.; Boguski, M. Functional genomics: It’s all how you read it. Science 1997, 278, 601-602.
Palson, B. O. What lies beyond bioinformatics? Nat. Biotechnol. 1997, 15, 3-4.
Ouzounix, C., Casari, G. Computational comparisons of model genomes. Trends Biotechnol. 1996, 14 (Aug), 280-285.
Bonarius, H.P.J., Schmid, G., Tramper, J. Flux analysis of underdetermined metabolic networks: the quest for the missing constraints. Trends Biotechnol. 1997, 15 (Aug) 308-314.
Plomin, Robert. Genetics and general cognitive ability.Nature 402 (suppl.): C25-C29.
http://www.dnaprint.com./index.cfm?fuseaction=content&id=250
Personalized Medicine and Pharmacogenomics
Doctors and pharmacists have long known that individuals respond differently to the same drug. The reason for this is the underlying genetic variability between individuals. Pharmacogenomics is the study of variable drug response against the backdrop of genetic variability and most properly involves a consideration of complex genetics (a good analogy to this system is the flux-balance model in E. Coli- Schilling et al., 1999). Whereas one person may effectively and safely metabolize a certain drug, another may metabolize the same drug into a dangerous toxin or not metabolize it well at all. By evaluating drug response against genotype, it will be possible to define genetic profiles that are compatible with certain treatment regimens and those which are not. In this way, a patient's response to a drug can be accurately predicted before the drug is prescribed. The idea of using a patient's genotype as a factor in deciding on treatment options is commonly referred to as Personalized Medicine. Though today's drugs are approved and developed based on their performance in a large population of people, medicine of the future will be evaluated and prescribed, tailor made for a particular patient's needs.
Copyright DNAPrint genomics © 2000
900 Cocoanut Ave.
Sarasota, FL 34236
(941) 366-3400
Fax # (941) 952-9770
home / company / medicine / science / services / advantages / technology
programs / investors / properties / careers / founders / order / contact / login
Spell check at bottom of "Text Box!"
"SNIPdoc" SNP discovery system
The Company maintains a cutting edge high throughput polymorphism-screening laboratory and the SNiPdoc(tm) system is the discovery search engine for this facility. SNiPdoc(tm) is a software system that designs vertical re-sequencing projects, aligns raw DNA sequence data from multiple donors, and uses proprietary statistical routines to find reliable discrepancies between these sequences. The data is formatted and deposited into a relational database system."
The software designs the re-sequencing (sequencing the same gene from multiple donors) of experiments starting with raw human genome data files (NCBI Genbank). The software system begins by defining "important" and "unimportant" regions of a human genome DNA sequence file, then designs primers to flank pertinent regions of the file through formatting these primers for easy oligonucleotide ordering from third party vendors. The software achieves in seconds what it previously took a scientist an hour or more to accomplish during the tedious process of experimental design. After primer design and amphfication, the software allows the company to identify reliable SNPs through a process called multiple sequence alignment and discrepancy validation. The output of the program is a list of SNPs in FASTA format for assay design. Our system has allowed us to create some of the most dense and reliable Gene polymorphism maps anywhere. Whereas publicly available SNPs validate as Polymorphisms at a rate of about 50-60%. Our result is greater than 95%.
Copyright DNAPrint genomics © 2000
900 Cocoanut Ave.
Sarasota, FL 34236
(941) 366-3400
Fax # (941) 952-9770
PhenomeTM SNiP databases
We have developed unique and comprehensive SNP databases through the use of proprietary, protocols and data mining techniques. At present, we are sequencing 1,000,000 bases of DNA per week. This rate of sequencing has allowed us to discover about 1 novel, quality validated SNP for every 200 bases of target sequence in the human genome. This rate of discovery is greater than that which others have reported in the scientific literature. In contrast to maps present in public resources, the proprietary SNP maps the company is building span the entire length of each target gene. Relatively few of the SNPs comprising these maps are present in public genome database resources. In addition, analysis conducted to date has validated these SNPs (as real polymorphisms) at a significantly higher rate than those taken or "mined" from public database resources. The Company attributes these desirable outcomes to its implementation of unique vertical re-sequencing protocols and proprietary software platform (the patent pending SNiPdoc(tm) system) for raw SNP discovery.
http://www.dnaprint.com./index.cfm?fuseaction=content&id=27
DNAPrint Inks Deal With Pharsight
http://money2.go.com/News?newsRef=Bizwire/20010824/a2133&ticker=ACEL,ADVR,ALLP,AQSE,DNAP,ENDV,LB...
October is a gloomy month for stocks and probably does not bode well for DNAP
either! September and October of this year would not seem to be months that I,
personally would want to see DNAP released goods news into. The lack of market
momentum would skew any news away from positive territory. I look for any news
regarding DNAP discoveries, as Dr. Tony said, to be given to us by year's end. In the
interim, we investors may have a few months to pick up DNAP shares at (imho)
ridiculously low s/p.
DNAPrint Awarded "High Tech Corridor" Grant
SARASOTA, Fla., Aug 2, 2001 /PRNewswire via COMTEX/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP) announced today that it has been awarded a "High Tech Corridor" grant by the University of South Florida (USF) Office of Economic Development. The grant proposal entitled "A Model System for Cancer Pharmacogenomics" was selected for funding under the USF 2001-2002 External Matching Grant program.
This program awards grants each year to outstanding companies located in the technology corridor of Florida. The aim of the grant program is to apply USF technology and resources for the promotion of economic growth in the state of Florida.
Dr. Hong-Gong Wang from the USF will serve as the principal investigator for the grant and, Hector Gomez, M.D., Ph.D and K. Ponnuswamy, Ph.D. will serve as the leaders for the project on the company side. The grant was written by DNAPrint's Dr. Tony Frudakis. The award provides $305,000 over the next year for the development of an innovative and powerful model system for defining the genetic variance components that underlie variable drug response. The Company intends to use the model system to guide and validate its large-scale population genetics research and product development efforts. If successfully developed and implemented, the model system would impart a significant competitive advantage to DNAPrint within the personalized medicine space.
About the Corridor Program:
The University of South Florida has established one of its mission priorities as promoting regional economic development. "Economic Development," in a higher education setting, signifies links to the public and private sector for the purposes of encouraging high-technology jobs for graduates, helping raise the standard of living through high-technology partnerships, linking with industry to promote funding and real-world applications for USF's research and academic standing, and in general identifying ways that the university can better meet the needs of the private sector and the region in general.
For more information about the Corridor, please visit http://w3.usf.edu./oed
About DNAPrint genomics Inc.:
DNAPrint genomics, Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The Company has a focused effort within the population genomics, informatics, and clinical fields for the application and production of patient-drug classification tests for personalized medicine. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contacts: For Scientific inquiries:
Tony Frudakis, Ph.D., 941/366-3400
or
Other inquiries
Tim Wilkins, 941/341-0136
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cpr%5C2001%5C08%5C02...